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ABSTRACT 
 
While envenoming by the southern African shield-nosed or coral snakes (genus 
Aspidelaps) has caused fatalities, bites are uncommon. Consequently, this venom is 
not used in the mixture of snake venoms used to immunise horses for the manufacture 
of regional SAIMR (South African Institute for Medical Research) polyvalent antivenom. 
Aspidelaps species are even excluded from the manufacturer’s list of venomous 
snakes that can be treated by this highly effective product. This leaves clinicians, albeit 
rarely, in a therapeutic vacuum when treating envenoming by these snakes. This is a 
significantly understudied small group of nocturnal snakes and little is known about 
their venom compositions and toxicities. Using a murine preclinical model, this study 
determined that the paralysing toxicity of venoms from Aspidelaps scutatus 
intermedius, A. lubricus cowlesi and A. l. lubricus approached that of venoms from 
highly neurotoxic African cobras and mambas. This finding was consistent with the 
cross-genus dominance of venom three-finger toxins, including numerous isoforms 
which showed extensive interspecific variation. Our comprehensive analysis of venom 
proteomes showed that the three Aspidelaps species possess highly similar venom 
proteomic compositions. We also revealed that the SAIMR polyvalent antivenom cross-
reacted extensively in vitro with venom proteins of the three Aspidelaps. Importantly, 
this cross-genus venom-IgG binding translated to preclinical (in a murine model) 
neutralisation of A. s. intermedius venom-induced lethality by the SAIMR polyvalent 
antivenom, at doses comparable with those that neutralise venom from the cape cobra 
(Naja nivea), which the antivenom is directed against. Our results suggest a wider than 
anticipated clinical utility of the SAIMR polyvalent antivenom, and here we seek to 
inform southern African clinicians that this readily available antivenom is likely to prove 
effective for victims of Aspidelaps envenoming. 
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INTRODUCTION 
 
The 81,000-138,000 estimates of the global mortality caused by snake 
envenoming include between 20,000-32,000 deaths in sub-Saharan Africa [1]. While 
the coagulopathic and haemorrhagic consequences of envenoming by Echis ocellatus 
saw-scaled (or carpet) vipers in West Africa and Bitis arietans puff adders throughout 
Africa account for most deaths, fatal envenoming by several neurotoxic Naja species of 
cobras and Dendroaspis species of mambas are also commonly reported [2]. Owing to 
the frequency of severe and fatal envenoming by these diverse snake species, their 
venoms are often mixed to hyper-immunise horses or sheep for the manufacture of 
polyspecific antivenom IgG to treat patients. The need to tailor antivenom production to 
envenoming by the most medically-important snakes, coupled with the costs of venom 
production and antivenom manufacture, typically translates to a lack of antivenom 
manufactured to treat tropical snake species that pose a relatively low 
mortality/morbidity risk. 
  The Aspidelaps coral and shield-nosed snakes of southern Africa is one such 
genus – none of the antivenoms manufactured for Africa include this venom in their 
manufacture [3] (WHO database 
http://apps.who.int/bloodproducts/snakeantivenoms/database/). Documented human 
fatalities, although rare, have occurred from both A. lubricus and A. scutatus [4, 5] and 
identify neurotoxic manifestations. In one case study, a 4-year-old female child who 
was bitten by a juvenile A. scutatus snake, became sub-comatose within two hours and 
was hyper-salivating and dysphonic. Respiratory collapse followed half an hour later 
and required mechanical ventilation but showed little improvement. Subsequently, the 
child did not survive a sudden cardiac arrest 16 hours post-envenomation [6]. In a 
second, a 30-year-old male bitten on the finger by a shield-nosed snake presented with 
symptoms of neurotoxicity, including progressive slurring of speech, drooping of both 
eyelids and impairment of respiratory muscles and ultimate recovery [7]. Another bite 
from a Namibian A. s. scutatus produced only cytotoxic symptoms, with swelling of the 
limb but no necrosis [8]. While a series of insignificant A. l. lubricus bites have been 
also described [9], the deaths of two indigenous Namibian children have been 
attributed to possible envenoming by A. l infuscatus [5]. 
Aspidelaps species are relatively small (50-75 cm long), robust and easily 
recognisable snakes and as a genus their distribution is restricted to Namibia, 
Botswana, Zimbabwe, Mozambique and South Africa. The name of the A. lubricus 
lubricus, southern coral snake and sub-species (A. l. infuscatus (western coral snake) 
and to a lesser extent, A. l. cowlesi (Cowle's shield snake)) reflects their red to orange 
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scale coloration and black cross-band patterns. The name of the A. s. scutatus, shield-
nose snake and two sub-species (A. s. fulafulus (eastern shield-nose snake) and A. s. 
intermedius (intermediate shield-nose snake)) refer to their much-enlarged rostral scale 
(for more herpetological detail see [4, 5, 10-13]. 
 The first toxinological study on Aspidelaps venom identified a phospholipase A2 
(PLA2) as the major component of A. scutatus venom [14]. A bibliographic search in 
PubMed found 10 hits for "Aspidelaps" between 1984 and 2018. Four of these papers 
reported the isolation, primary structures and some properties of A. scutatus venom 
proteins, including PLA2s CM-I, CM-II [P07037] and CM-III [15] and S2C1 and S2C2 [16]; 
long neurotoxin S4C6 [P25670] [17]; and putative cytotoxin homologues S3C1, S3C2 
[P19003], S3C3, S4C1, S4C7 and S4C8 [P19004] [18]. 
 The i.v. median murine lethal dose (LD50) for A. scutatus venom was 11.5-13 
g/mouse [14] and 1.7 ± 0.5 g/mouse for the isolated PLA2 proteins, CM-I=CM-II, and 
1.1 ± 0.5 g/mouse for CM-III [15]. The LD50 for the isolated long neurotoxin S4C6 (2.2 
± 0.04 g/mouse) was lower than the cytotoxin homologues (6.6-54 g/mouse) and the 
functionally unspecified S4C1 (LD50 3.6 g/g mouse) and S4C7 (LD50 0.25 g/g mouse) 
exhibited, respectively, the lowest and highest toxicity [16-18]. The recorded i.v. venom 
LD50 of 6 g/mouse for A. l. cowlesi [4, 19] is comparable to those of the Cape cobra 
(Naja nivea, 7 g/mouse) and black mamba (Dendroaspis polylepis, 5 g/mouse) [20, 
21; http://snakedatabase.org]. 
While the above historical literature reveals some penetrating insight to specific 
venoms and their toxins, there remain significant gaps in our knowledge of this 
enigmatic genus of venomous snakes. We therefore carried out multidisciplinary, 
multispecies analyses to define and compare the venom proteomes (underpinned by 
comprehensive venom gland transcriptomics) of the intermediate shield-nose snake (A. 
s. intermedius), southern coral snake (A. l. lubricus), and Cowle's shield snake (A. l. 
cowlesi); assessing the mechanism of action underpinning lethality by A. s. intermedius 
in the murine system, and the neutralisation of its toxicological effects by SAIMR 
polyvalent antivenom. 
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EXPERIMENTAL SECTION  
 
Biological materials 
 
Venom was extracted from (i) a single adult specimen of the intermediate shield-nose 
snake (Aspidelaps scutatus intermedius), (ii) six Cowle's shield snakes (Aspidelaps 
lubricus cowlesi), and (iii) four Cape coral snakes (Aspidelaps lubricus lubricus). All 
snakes were captive bred and maintained in individual cages within the temperature, 
humidity and light-controlled environment of the herpetarium of the Alistair Reid Venom 
Research Unit at the Liverpool School of Tropical Medicine. This facility and its 
protocols for the expert husbandry of the snakes is inspected and approved by the UK 
Home Office and the LSTM Animal Welfare and Ethical Review Board. The number of 
snakes used in this study was the maximum possible given the limited availability of 
these animals in our facility. Three days after venom extraction, venom glands were 
dissected from the single specimen of the intermediate shield-nose snake (A. s. 
intermedius) following terminal anaesthesia (Pentaject), and immediately snap frozen 
in liquid nitrogen. For immunological analyses we used the SAIMR (South African 
Institute for Medical Research) polyvalent snake antivenom manufactured by South 
African Vaccine Producers (Pty), Ltd. (Johannesburg, South Africa). This IgG-derived 
F(ab’)2 antivenom is made by immunising horses with venom from the following snake 
species: Bitis arietans and B. gabonica (family Viperidae) and Dendroaspis 
angusticeps, D. jamesoni, D. polylepis, Hemachatus haemachatus, Naja annulifera, N. 
melanoleuca, N. mossambica and N. nivea (family Elapidae). 
 
Transcriptomics  
  
We constructed the A. s. intermedius venom gland transcriptome using the methods 
previously described by our group [22, 23]. Briefly, the venom gland tissue was 
homogenised under liquid nitrogen using a pestle and mortar and a TissueRuptor 
(QIAGEN), and total RNA was extracted using the TRIzol Plus RNA Purification 
System (Thermofisher) protocol. The RNA samples were DNAse treated (On-Column 
PureLink DNase; Life Technologies) and total RNA eluted in 30µL nuclease free water 
(QIAGEN). Total RNA underwent two rounds of poly(A) selection using the Dynabeads 
mRNA DIRECT purification kit (Life Technologies), and was then eluted in nuclease 
free water, before the quality and quantity of isolated RNA was assessed using a 
Bioanalyzer (Agilent). One µL of the resulting total RNA was loaded onto an Agilent 
RNA 6000 Nano Chip and inserted into the Agilent 5000 Bioanalyzer for analysis. 
Agilent RNA 2100 Expert software was used to calculate total RNA concentration and 
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assign a RNA integrity number (RIN) [24]. Subsequently, the sequencing library was 
prepared using 50 ng of enriched RNA using the Script-Seq v2 RNA-Seq Library 
Preparation Kit (epicenter), following 12 cycles of amplification. The sequencing library 
was then purified using AMPure XP beads (Agencourt), quantified using the Qubit 
dsDNA HS Assay kit (Life Technologies) and the size distribution assessed using a 
Bioanalyser (Agilent). Sequencing libraries were multiplexed with others not reported in 
this study, and sequencing performed on an Illumina MiSeq platform using 250bp 
paired-end reads technology (Centre for Genomics Research, University of Liverpool). 
The A. s. intermedius sample represented 1/6th of this sequencing lane and resulted in 
5,664,906 reads. The ensuing read data was quality processed as previously 
described [22, 23, 25, 26], resulting in the removal of adapter sequences (Cutadapt; 
https://code.google.com/p/cutadapt/) and low quality bases (Sickle; 
https://github.com/najoshi/sickle). Paired-end read data were then assembled into 
contigs using VTBuilder [27] with the following parameters: min. transcript length 150 
bp; min. read length 150bp; min. isoform similarity 96%. As part of this process, the 
VTBuilder algorithm also generates relative transcript expression data via a normalised 
read mapping approach [27]. The resulting assembled contigs were annotated using 
BLAST2GO Pro v3 [28] using the blastx-fast algorithm with a significance threshold of 
1e-5 against NCBI’s non-redundant (NR) protein database (41 volumes, Nov 2015). 
Following annotation, contigs were grouped into the following categories: toxins 
(contigs with blast annotations to sequences previously described as pathogenic 
toxins), non-toxins (contigs matching other sequences, such as housekeeping genes) 
and unassigned (those with no matches assigned or hits <1e-5). Where toxin contigs 
exhibited 100% identity to one another in overlapping regions (>50bp long), indicative 
of underclustering, the contigs and their expression levels were merged. Raw 
sequence reads have been deposited in the NCBI sequence read archive (SRA) under 
accession SRP153153 and linked to the BioProject identifier PRJNA480570. 
Assembled toxin-coding contigs are found in Supplementary Table S1.  
 
Isolation and proteomics characterisation of venom peptidome and proteome  
 
Two milligrams of crude, lyophilised venom were dissolved in 200 μL of 5% acetonitrile 
in water containing 0.1% trifluoroacetic acid (TFA), centrifuged to remove debris, and 
separated by reverse-phase HPLC using a Teknokroma Europa Protein 300 C18 (0.4 
cm × 25 cm, 5 m particle size, 300 Å pore size) column and an LC 1100 High 
Pressure Gradient System (Agilent Technologies, Santa Clara, CA, USA) equipped 
with DAD detector and micro-Auto-sampler. The flow-rate was set to 1 mL/min and the 
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column was developed with a linear gradient of 0.1% TFA in water (solution A) and 
acetonitrile (solution B) using the following column elution conditions: isocratically (5% 
B) for 5 min, followed by 5%–25% B for 10 min, 25%–45% B for 60 min, and 45%–70% 
for 10 min. Protein detection was carried out at 215 nm with a reference wavelength of 
400 nm. Fractions were collected manually, dried in a vacuum centrifuge (Savant), 
redissolved in water, and submitted to electrosprayn ionisation (ESI) molecular mass 
determination. To this end, intact peptides and proteins eluted in each RP-HPLC 
fraction were separated by nano-Acquity UltraPerformance LC® (UPLC®, Waters 
Corporation, Milford, MA, USA) using BEH130 C18 (100 μm × 100 mm, 1.7 μm particle 
size) column in-line with a SYNAPT® G2 High Definition Mass Spectrometry System 
(Waters Corp. Milford, MA, USA). The flow rate was set to 0.6 μL/min and the column 
was developed with a linear gradient of 0.1% formic acid in water (solution A) and 0.1% 
formic acid in acetonitrile (solution B), isocratically 1% B for 1 min, followed by 1%–
12% B for 1 min, 12%–40% B for 15 min, 40%–85% B for 2 min. Isotope-averaged 
molecular masses were calculated from manually deisotoperd and deconvoluted ESI 
mass spectra.  
  Chromatographic fractions were also analysed by SDS-PAGE in 15% 
polyacrylamide gels, under reducing and non-reducing conditions. Gels were stained 
with Coomassie Brilliant Blue R-250 (Sigma-Aldrich, St. Louis, MO, USA). 
Electrophoretic protein bands were excised from Coomassie Brilliant Blue-stained 
SDS-PAGE gels and subjected to in-gel reduction (10 mM dithiothreitol) and alkylation 
(50 mM iodoacetamide) before overnight sequencing-grade trypsin digestion (66 ng/μL 
in 25 mM ammonium bicarbonate, 10% acetonitrile; 0.25 μg/sample) in an automated 
ProGest Protein Digestion Workstation (Genomic Solution Ltd., Cambridgeshire, UK) 
following the manufacturer’s instructions. Tryptic digests were dried in a SpeedVac 
(Savant™, Thermo Scientific Inc., West Palm Beach, FL, USA), redissolved in 15 μL of 
0.1% formic acid in water, and submitted to LC-MS/MS. To this end, tryptic peptides 
were separated by nano-Acquity UltraPerformance LC® (UPLC®) using BEH130 C18 
(100 μm × 100 mm, 1.7 μm particle size) column in-line with a SYNAPT® G2 High 
Definition Mass Spectrometry System (Waters Corp. Milford Massachusetts, USA), run 
under the same chromatographic conditions as above. Doubly, triply and quadruply 
charged ions were selected for collision-induced dissociation (CID) MS/MS. 
Fragmentation spectra were interpreted (a) manually (de novo sequencing); (b) using 
the on-line form of the MASCOT program at http://www.matrixscience.com against the 
NCBI non-redundant database; and (c) processed in Waters Corporation’s ProteinLynx 
Global SERVER 2013 version 2.5.2 (with Expression version 2.0) against the 
Aspidelaps scutatus intermedius venom gland transcriptomic database. MS/MS mass 
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tolerance was set to ± 0.6 Da. Carbamidomethyl cysteine and oxidation of methionine 
were selected as fixed and variable modifications, respectively. Amino acid sequence 
similarity searches were performed against the available databanks using the BLAST 
program implemented in the WU-BLAST2 search engine at http://www.bork.embl-
heidelberg.de. 
 The relative abundances (expressed as percentage of the total venom proteins) 
of the different protein families were calculated as the ratio of the sum of the areas of 
the reverse-phase chromatographic peaks containing proteins from the same family to 
the total area of venom protein peaks in the reverse-phase chromatogram [29, 30]. 
When more than one protein band was present in a reverse-phase fraction, their 
proportions were estimated by densitometry of Coomassie-stained SDS-
polyacrylamide gels using ImageJ version 1.47 (http://rsbweb.nih.gov/ij). Conversely, 
the relative abundances of different proteins contained in the same SDS-PAGE band 
were estimated based on the relative ion intensities of the three more abundant peptide 
ions associated with each protein by MS/MS analysis. Finally, protein family 
abundances were estimated as the percentages of the total venom proteome. 
 
Immunological assays 
 
1D SDS-PAGE gel electrophoresis and immunoblotting 
For one-dimensional (1D) SDS-PAGE gel electrophoresis and immunoblotting we 
followed our recently described protocol [20, 31]. Briefly, we mixed 10 µg of each 
venom with a 1:1 ratio of reduced protein loading buffer, before incubating the samples 
at 100°C for 10 minutes. The samples were then loaded onto 10-well Mini-PROTEAN 
TGX precast AnykD gels (Bio-Rad), alongside 5 µl of protein marker (Broad Range 
Molecular Marker, Promega), and run at 100 V for 90 minutes using a Mini-PROTEAN 
Tetra System (Bio-Rad). Resulting proteins gels were: (i) stained with coomassie 
brilliant blue overnight and then destained (4.5:1:4.5 methanol:acetic acid:H2O) for 
visualisation, and (ii) transferred to 0.45 µm nitrocellulose membranes for 
immunoblotting experiments using a Trans-Blot Turbo Transfer System (Bio-Rad). For 
immunoblotting, following confirmation of successful protein transfer by reversible 
Ponceau S staining, the membranes were incubated overnight in 5% non-fat milk in 
TBST buffer (0.01 M Tris-HCl, pH 8.5; 0.15 M NaCl; 1% Tween 20) and then washed 
six times in TBST over 90 mins, before incubation overnight at 4°C with the primary 
antibodies (SAIMR polyvalent antivenom) diluted 1:5,000 in 5% non-fat milk in TBST. 
Blots were washed again and incubated for 2 hr at room temperature with rabbit anti-
horse horseradish peroxidase-conjugated secondary antibodies (Sigma-Aldrich) diluted 
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1:2,000 in PBS. After a final TBST wash, immunoblots were visualised with the addition 
of DAB substrate (50 mg 3,3-diaminobenzidine, 100 ml PBS, 0.024% hydrogen 
peroxide) for 10 sec. 
 
End-point titration and avidity ELISAs 
For end point titration ELISAs, we used our previously described protocols [20, 32]. In 
brief, 96 well, flat bottomed, ELISA plates (Nunc) were coated with 100 ng of each 
venom prepared in carbonate buffer, pH 9.6 and the plates incubated at 4°C overnight. 
Plates were washed after each stage, using six changes of TBST (0.01 M Tris-HCl, pH 
8.5; 0.15 M NaCl; 1% Tween 20). Plates were then incubated at room temperature 
(RT) for 3 hours with 5% non-fat milk (diluted with TBST) to ‘block’ non-specific 
reactivity, before washing and incubation with SAIMR polyvalent antivenom overnight 
at 4°C. The addition of primary antibodies was performed in triplicate with an initial 
dilution of 1:100 followed by 1:5 serial dilutions. Plates were washed and then 
incubated in horseradish peroxidase-conjugated rabbit anti-horse IgG (1:2,000; Sigma) 
for 3 hours at RT. Following washing, the results were visualized by the addition of 
substrate (0.2% 2,2/-azino-bis (2-ethylbenzthiazoline-6-sulphonic acid) in citrate buffer, 
pH 4.0 containing 0.015% hydrogen peroxide (Sigma, UK) and optical density (OD) 
measured at 405nm. The end point titre was defined as the dilution at which the 
absorbance was greater than that of the baseline plus two standard deviations. 
      The avidity ELISA was performed as above except that the SAIMR polyvalent 
antivenom was diluted to a single concentration of 1∶12,500, incubated overnight at 
4°C, washed with TBST and the chaotrope, ammonium thiocyanate, added to the wells 
in a range of concentrations (0–8 M) for 15 minutes. Plates were washed, and all 
subsequent steps were the same as the end point titration ELISA. The relative avidity 
was determined as the concentration of ammonium thiocyanate required to reduce the 
control ELISA OD reading (with no chaotrope) by 50%. 
 
Third-generation antivenomics 
Third-generation antivenomics [33] was applied to assess the immunoreactivity of the 
SAIMR antivenom against venom from A. l. lubricus and A. l. cowlesi. One vial of 
antivenom was dissolved in 10 mL of the supplied diluent, dialysed against MilliQ® 
water, lyophilised, and reconstituted in 10 mL of 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3 
(coupling buffer). The concentrations of the antivenom stock solution was determined 
spectrophotometrically using an extinction coefficient for a 1 mg/mL concentration 
(ε0.1%) at 280 nm of 1.36 (mg/mL)-1 cm-1 [34]. Antivenom affinity columns were prepared 
in batch. Three mL of CNBr-activated Sepharose™ 4B matrix (Ge Healthcare, 
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Buckinghamshire, UK) were packed in a ABT column (Agarose Bead Technologies, 
Torrejón de Ardoz, Madrid) and washed with 10x matrix volumes of cold 1 mM HCl, 
followed by two matrix volumes of coupling buffer to adjust the pH to 7.0-8.0. CNBr-
activated instead of N-hydroxysuccinimide (NHS)-activated matrix was employed 
because NHS released during the coupling procedure absorbs strongly at 280 nm, thus 
interfering with the measurement of the concentration of antibodies remaining in the 
supernatant of the coupling solution. Forty mg of antivenom was dissolved in 2x matrix 
volume of coupling buffer and incubated with 3 mL of CNBr-activated matrix for 4 h at 
room temperature. Antivenom coupling yield, estimated measuring A280nm before and 
after incubation with the matrix, was 19.9 mg/mL. After the coupling, remaining active 
matrix groups were blocked with 12 mL of 0.1 M Tris-HCl, pH 8.5 at room temperature 
for 4 h. Affinity columns, each containing 352 µL (7.0 mg) of immobilised antivenom, 
were alternately washed with three matrix volumes of 0.1 M acetate containing 0.5 M 
NaCl, pH 4.0-5.0, and three matrix volumes of 0.1 M Tris-HCl, pH 8.5. This procedure 
was repeated 6 times. The columns were then equilibrated with 5 volumes of working 
buffer (PBS, 20 mM phosphate buffer, 135 mM NaCl, pH 7.4) and incubated with 
increasing amounts (100-1200 μg of total venom proteins) of venom dissolved in ½ 
matrix volume of PBS, and the mixtures incubated for 1 h at 25 °C in an orbital shaker. 
As specificity controls, 350 μL CNBr-activated Sepharose™ 4B matrix, without (mock) 
or with 7 mg of immobilised control (naïve) horse IgGs, were incubated with venom and 
developed in parallel to the immunoaffinity columns. The non-retained eluates of 
columns incubated with 100-600 μg and 900-1200 μg venom were recovered with 5x 
and 10x matrix volume of PBS, respectively, and the immunocaptured proteins were 
eluted, respectively, with 5x and 10x matrix volume of 0.1M glycine-HCl, pH 2.7 buffer 
and brought to neutral pH with 1M Tris-HCl, pH 9.0. The entire fractions eluted with 5x 
and ½ of the fractions recovered in 10x matrix volume were concentrated in a Savant 
SpeedVac™ vacuum centrifuge (ThermoFisher Scientific, Waltham, MA USA) to 40 μL, 
and aliquots corresponding to 150 initial total venom proteins were fractionated by 
reverse-phase HPLC using an Agilent LC 1100 High Pressure Gradient System (Santa 
Clara, CA, USA) equipped with a Discovery® BIO Wide Pore C18 (15 cm x 2.1 mm, 3 
μm particle size, 300 Å pore size) column and a DAD detector as above. Eluate was 
monitored at 215 nm with a reference wavelength of 400 nm. The fraction of non-
immunocaptured molecules was estimated as the relative ratio of the chromatographic 
areas of the toxin recovered in the non-retained (NR) and retained (R) affinity 
chromatography fractions using the equation  
%NRi=100-[(Ri/(Ri+NRi)) x 100],  
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where Ri corresponds to the area of the same protein "i" in the chromatogram of the 
fraction retained and eluted from the affinity column. 
Toxicity and neutralisation assays 
 
All in vivo animal experimentation was conducted using protocols approved by the 
Animal Welfare and Ethical Review Boards of the Liverpool School of Tropical 
Medicine and the University of Liverpool, and performed in specific pathogen free 
conditions under licenced approval (PPL4003718) of the UK Home Office, in 
accordance with the Animal [Scientific Procedures] Act 1986 and institutional guidance 
on animal care. Experimental design was based upon refined WHO-recommended 
protocols [20, 32, 35, 36].  
In vivo venom toxicity 
We determined the median lethal dose (venom LD50) of A. s. intermedius and N. nivea 
venom, using the previously described method [20, 32]. Briefly, groups of five male 18-
22g CD-1 mice (Charles River, UK) received varying doses of each venom in 100 μl 
PBS via intravenous (tail vein) injection, and after 7 hr surviving animals were 
recorded. Animals were continuously monitored for the duration of the experiment and 
euthanised upon observation of humane endpoints (e.g. external signs of 
haemorrhage, seizure, pulmonary distress, paralysis). The amount of venom that 
causes lethality in 50% of the injected mice (the LD50) and the 95% confidence 
intervals were calculated using probit analysis [37]. Due to limited venom supplies, and 
also to reduce experimental animal numbers, we only performed limited range-finding 
venom toxicity studies with the other Aspidelaps venoms. We tested the toxicity of A. l. 
lubricus venom at four different doses, each in a single experimental animal, while A. l. 
cowlesi venom was delivered to two mice at a single dose of 5 µg. Euthanised animals 
from the experiments described above were subjected to post-mortem macroscopic 
examination, with gross pathology recorded. 
In vivo venom neutralisation 
To assess the efficacy of the SAIMR polyvalent antivenom at neutralising the lethal 
effects of Aspidelaps venom we used the median effective dose (ED50) assay; a WHO-
recommended test for determining the least amount of antivenom required to prevent 
death in 50% of mice injected with lethal doses of venom [36, 38]. Using a previously 
described protocol [20, 32], various doses of the SAIMR polyvalent antivenom were 
mixed with 2 x LD50s of A. s. intermedius (2 x LD50 = 11.5 µg) or N. nivea venom (2 x 
LD50 = 30.1 µg) in 200 μl PBS, and the mixture incubated at 37°C for 30 minutes. As 
described above, the mixture was then intravenously injected into the tail vein of 
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groups of five male 18-22g CD-1 mice and after 7 hr the surviving animals were 
recorded. The median effective dose (ED50) and 95% confidence limits were calculated 
using probit analysis [37]. 
 
 
RESULTS AND DISCUSSION 
 
The Aspidelaps scutatus intermedius venom gland transcriptome 
Sequencing of the A. s. intermedius venom gland transcriptome resulted in 2,523 
assembled contigs. Using BLAST annotations, we classified these contigs into three 
categories: those encoding toxin families previously described in the literature, those 
encoding non-toxin ‘housekeeping’ genes, and those with no significant BLAST hit. 
Consistent with other previously described snake venom gland transcriptomes [39-44], 
toxin encoding contigs accounted for the majority of gene expression observed (54.6%, 
Fig. 1), despite being represented by a small proportion of the contigs (66 contigs, 
3.3% of total contig numbers). In contrast, we recovered 1,783 contigs encoding non-
toxins, which represented 41.6% of total transcriptome expression, and a total of 674 
contigs (4.0% of total expression) that exhibited no significant hit to sequences in the 
NCBI NR database (Fig. 1). 
In line with previous venom gland transcriptomic studies on elapid snakes [22, 42, 
45], we observed considerable toxin gene complexity. A total of 17 different toxin-
encoding gene families were identified (Fig. 1, Supplementary Table S1), although only 
five of these, three-finger toxin (3FTx), phospholipase A2 (PLA2), Kunitz-type inhibitor 
(KUN), cysteine-rich secretory protein (CRISP) and C-type natriuretic peptides 
precursor (C-NP prec) exhibited expression levels of >1% of all toxin encoding mRNAs, 
and only two (3FTx and PLA2) exhibited total toxin transcript expression levels of >3% 
(Fig. 1, Supplementary Table S1). 3FTxs were the dominant toxin-coding transcript 
type recovered, both in expression level (65.3% of total toxin mRNAs) and number of 
family members, with 27 unique contigs encoding 23 different (19 full-length) 3FTx 
proteins (Table S1). BLAST-based structural annotations included cytotoxins (CTxs), 
aminergic (muscarinic) toxins (MTxs), type I (short) and type II (long) neurotoxins 
(NTxs), weak toxins (WTxs) and a pre-synaptic bucandin-like neurotoxin. CTx S4C8 and 
two isoforms of CTx S3C2 (Joubert, 1988c), each representing 22-24% of total toxin 
transcripts expression (12-13% of the total venom gland transcriptome), were the most 
abundant 3FTx-coding mRNAs (Fig. 1, Table S1).  
 The second most abundant gene family expressed in the venom gland 
transcriptome of A. s. intermedius was PLA2. This toxin transcript class represented 
23.8% of total toxin transcripts expression (13% of the total venom gland 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 13 
transcriptome), which encoded 1-2 putative isocontigs (e.g. contigs differing in a single 
nucleotide) for the group IA acidic PLA2 CM-II [P07037] [15] (Fig. 1, Table S1). 
Whether these single nucleotide variants mirror the existence of two highly similar gene 
products or results from a sequencing error remains obscure. The remaining 14 venom 
toxin transcript families exhibited lower expression levels, with each representing less 
than 3% of the total abundance of toxin encoding contigs and, in combination, 
representing <11% of all toxin-coding mRNAs (Fig. 1, Table S1). Amongst these lowly 
expressed genes, the four KUN contigs accounted for 2.54% of all toxin transcripts, 
making it the third most abundant toxin gene family. Contigs T0353, T0399 and T1458 
encoded single Kunitz-domains and, in combination, dominate the KUN expression 
detected (2.51%). Contig T0053 encoded two tandemly arranged Kunitz domains 
exhibiting sequence similarity with the unusual two-domain Kunitz-type proteinase 
inhibitor reported from the South Australian Kangaroo Island endemic pygmy 
copperhead (Austrelaps labialis) venom gland [46]. All remaining putative toxin 
transcript types identified in the A. s. intermedius venom gland transcriptome were 
found expressed at very low levels (<1.4% of the total toxin encoding genes) and 
included: six SVMP contigs, four C-NP precursor contigs, and single contigs encoding 
full-length cysteine-rich secretory protein (CRISP), nawaprin (NAW), cobra venom 
factor (CVF), phospholipase B (PLB), phosphodiesterase (PDE), vespryn, snake 
venom serine protease (SVSP), nerve growth factor (NGF), L-amino acid oxidase, 
dipeptidyl peptidase IV (DPP IV), 5’-nucleotidase (5'-NT), and hyaluronidase (HYAL) 
(Fig. 1, Table S1). Altogether the transcriptomic dataset consists of 66 contigs merged 
into 51-53 toxin-coding mRNAs, of which 41 include full-length toxin sequences (Table 
S1). 
 
The divergent venom proteomes of A. s. intermedius and A. lubricus subspecies 
The venom proteomes of adult A. s. intermedius, A. l. lubricus, and A. l. cowlesi 
specimens were characterized and quantified applying the previously described [29, 
30] two-step pre-MS decomplexation protocol (reverse-phase HPLC and SDS-PAGE) 
(Fig. 2, panels A, C and E), followed by peptide-centric bottom-up, transcriptome-aided 
MS/MS analysis of tryptic digests from SDS-PAGE separated protein bands eluted in 
the different RP chromatographic fractions [47].   
 Comparative proteomics analysis revealed a high degree of conservation of the 
global composition of the three Aspidelaps venom proteomes (Fig. 2), all characterized 
by the overwhelming predominance of 3FTxs (76-83% of the total venom toxins). All 
three venoms shared modest to moderate relative abundance of KUN (1-9%), PLA2 (5-
6%), CRISP (3.5-5%), PIII-SVMP (3-5%), and PDE (0.4-1%). svNGF was found in A. s. 
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intermedius (1.7%) and A. l. lubricus (0.1%) (Fig. 2 panels B and D, respectively), 
whereas LAO was equally (1%) present in both subspecies of A. lubricus (Fig. 2, 
panels D and F, respectively), and a low amount of HYAL (0.1%) was uniquely 
identified in the venom of A. l. cowlesi (Fig. 2, panel F). Supplementary Tables S2-S4 
provide details of the assignment, quantification, and matching to the transcriptomic 
database of the RP-HPLC separated venom proteins of A. s. intermedius, A. l. lubricus, 
and A. l. cowlesi, respectively. Isotope-averaged masses of intact A. l. cowlesi toxins 
were also recorded by ESI LC-MS (Supplementary Table S4).     
 Proteomic hits were predominately matched to transcriptome contigs and the 
closest homolog toxin present in the NCBI database was identified by BLAST analysis. 
The picture that emerged when the relative abundances of the different 3FTx classes 
were mapped on the species' pie charts revealed distinct compositional patterns for A. 
s. intermedius on the one hand and the A. lubricus subspecies on the other. Thus, 
whereas the venom proteome of A. s. intermedius is mostly composed of cytotoxins 
(S4C8 and S3C2, 33.7%) and post-synaptic -neurotoxins of type I (short -NTx-1 and 
atratoxin b [N. annulifera P68417]-like, 12.5%) and type II (long-chain NTx-1 S4C6 and 
-NTx, 31.2%) (Fig. 2B), the venoms from both A. lubricus subspecies contain lower 
proportion of cytotoxins (S3C2, 2-5%; S4C8, absent) and higher concentrations (22-26%) 
of -neurotoxin(s) homologous to the Chinese cobra N. atra atratoxin b [AAR33036] 
and long-chain NTx-1 S4C6 (40-42%) (Fig. 2, panels D and F). In addition, a weak 
neurotoxin (homolog of N. haje wNTx CM-II, 1.8%) identified in the venom of A. s. 
intermedius was absent from the A. lubricus venoms, which, in turn, present non-
conventional (nc) 3FTxs (2-3%) similar to Bungarus flaviceps ADF50020, and a pre-
synaptic neurotoxic 3FTx (-NTx, 1-2%) homolog of  B. candidus bucandin [P81782], 
which was not found in the venom of A. s. intermedius.  
 Comparison of the toxin composition of A. s. intermedius venom gland 
transcriptome and venom proteome revealed both qualitative and quantitative 
differences. Thus, several putative toxin families observed in the transcriptome were 
not detected in the venom proteome (Fig. 1). On the other hand, the major 
discrepancies between gene expression and proteomic abundance correspond to the 
3FTx class, which experience a net increase of 15.2%, while the acidic PLA2 CM-II 
[P07037], decreased by 17.7% (Table 1). Among the 3FTxs, the change of expression 
is disparate. While long NTx-1 S4C8 increased its relative abundance by 10-fold (T, 
2.8%; P, 28.9%), the relative abundance of CTx S3C2 decreased from 23.8% (T) to 
10.5% (P), whereas the level of expression of CTx S4C8 remained constant (T = P, 
22%) (Table 1). These major changes between gene expression and proteomic 
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abundance may result from post-transcriptional modulation of mRNA translation [48-
50], although further studies are needed to address this issue. 
 The Aspidelaps venom proteomes, dominated by cytotoxic and/or neurotoxic 
3FTxs, seemingly account for the reported neurological (A. l. lubricus) and cytotoxic (A. 
s. scutatus) manifestations of the few documented Aspidelaps snakebite envenomings 
described from humans [4-9], and from experimental studies in mice [5]. To delve into 
the mechanism of action underpinning lethality by Aspidelaps venom we determined 
the toxicity of Aspidelaps venom in vivo, and performed behavioural observations of 
envenomed mice and assessments of post-mortem pathology.   
 
Toxicity and toxicovenomics of Aspidelaps venoms 
To determine the toxicity of Aspidelaps venom in vivo, we intravenously (i.v.) injected 
groups of mice with varying doses of A. s. intermedius venom. The i.v. murine lethal 
dose 50 (LD50) of A. s. intermedius venom was found to be 5.75 µg/mouse (5.29–6.26 
µg, 95% CI [0.2875 mg/kg]), which is more potent than that obtained with N. nivea 
venom (15.05 µg/mouse [10.20–18.70 95% CI]; 0.7525 mg/kg). Consequently, the 
murine toxicity of A. s. intermedius venom is highly comparable with some of the most 
toxic, medically important, elapid snakes of sub-Saharan Africa (e.g. D. polylepis 6.17 
µg/mouse; N. haje 8.15 µg/mouse; N. pallida 9.29 µg/mouse; [20, 22]. Limited range-
finding toxicity experiments with venom from A. l. lubricus suggested a comparable 
LD50 with than of A. s. intermedius (four mice tested at different doses; survival at 2 
µg/mouse and death at 5 µg/mouse). Equivalent experiments with A. l. cowlesi venom 
were inconclusive due to insufficient venom - two mice were tested and both survived a 
dose of 5 µg. Nevertheless, the data suggested a lower toxicity than its congeners in 
the murine model. 
 Taking advantage of the availability of LD50 values for the major individual toxins 
and 3FTx subfamilies identified in the Aspidelaps venoms (Fig. 2), we applied a 
toxicovenomics approach to calculate theoretical LD50s for the three Aspidelaps 
venoms (Table 2). To this end, the contribution of a given toxin "i" to the venom's LD50 
was calculated as 
ƒLD50 Toxin"i" = (%Toxin"i") x (LD50 Toxin"i") 
 
The combined contribution of toxins other than 3FTxs and PLA2 (eg, "other Txs" = 
KUN, CRISP, PIII-SVMP, PDE, LAO, HYAL and vNGF) was estimated for A. s. 
intermedius as 20g/g mouse using the equation:  
 
ƒLD50"otherTxs" = (Experimental LD50 Asi - ƒLD50 Toxin"i") / (%"otherTxs") 
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This value was used in the calculations of the theoretical LD50s for A. l. lubricus and A. 
l. cowlesi venoms, resulting in 4.12-6.45 g/g and 4.18-5.75 g/g, respectively (Table 
2). The good correspondence between these theoretical values and those determined 
on the basis of partial experimental data suggests that synergies between different 
toxins may not play a significant role in the toxicity of Aspidelaps venoms, as has been 
shown for other venoms [51-53]. 
 
Pathological effects induced by A. s. intermedius venom 
To assess the mechanism of action underpinning lethality by Aspidelaps venom, 
we performed (i) behavioural observations of envenomed mice and (ii) assessments of 
post-mortem pathology. At doses of 5-7 µg of A. s. intermedius venom all mice 
exhibited classical signs of systemic neurotoxicity with respiratory paralysis, 
characterised by ataxia, slumping and dyspnoea. Neurologically, this behaviour is 
consistent with blockade of neuromuscular transmission by either inhibition of binding 
to cholinergic receptor or damage to the presynaptic nerve terminal. Sixty minutes after 
administration of the 7 µg venom dose, all of the mice were euthanised on ethical 
grounds. Post-mortem analysis of mice i.v. injected with 6 µg and 7 µg of A. s. 
intermedius venom revealed the collapse of both lungs (n=6). Without further analysis, 
it is not possible to determine which of the toxins is responsible for the observed 
neurotoxicity. However, given the notable abundance of both type I and II post-synaptic 
3FTx neurotoxins detected in the venom, which are capable of targeting both 
neuromuscular and neuronal nicotinic acetylcholine receptors [54, 55], it seems 
reasonable to assume that these toxins are at least partially responsible.  
All experimental animals also exhibited evidence of haemorrhage into the atria 
(n=6), with seemingly selective sub-epicardial haemorrhage of the right ventricle (no 
abnormality was detected in the left ventricle) in the majority (4/6) of mice. 
Furthermore, incoagulable blood was observed in 3/6 mice, haemoperitoneum (blood 
within the peritoneal cavity) observed for 2/6 mice, and substantial haemothorax (free 
blood in chest cavity) observed in one mouse; suggesting that in addition to neurotoxic 
venom toxins, a notable cardiotoxic and haemotoxic component exists in the venom of 
A. s. intermedius. No obvious abnormalities were observed in the intestines, spleen, 
stomach, kidneys or brain, but haemorrhage was observed in the membranes 
surrounding the brain.  
Proteins of the 3FTx family are amongst the most functionally diverse groups of 
snake venom toxins, exhibiting a wide variety of pharmacological effects including 
neurotoxic, cytotoxic, cardiotoxic, anticoagulant, and antiplatelet activities [55, 56]. 
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Cardiotoxic 3FTxs exert their toxicity by forming pores in cell membranes [57], and 
both cardiotoxic and anticoagulant PLA2 molecules have been also characterized in 
snake venoms [52, 58]. Future toxicovenomic analysis of the cytotoxins S2C3 and S4C8 
and the PLA2 CM-II should reveal the pathophysiological relevance of these toxins in 
the cardiotoxic and haemotoxic effects produced by the administration of A. s. 
intermedius venom. 
 
Immunological cross-reactivity of Aspidelaps venoms with SAIMR polyvalent 
antivenom 
Antivenom is the treatment of choice for the neurotoxic and haemotoxic effects of 
systemic snake envenoming, and its efficacy is generally considered to be 
predominately restricted to the snakes whose venom was used in its manufacture or, in 
some cases, their congeners [1, 32, 59-62]. No commercial antivenom is made using 
venom from species of the genus Aspidelaps. The South African Vaccine Producers 
“SAIMR polyvalent” antivenom is generated by immunising horses with the venoms of 
related African species of Elapidae [63], including species from the genera Naja (Naja 
nivea, N. melanoleuca, N. annulifera and N. mossambica), Hemachatus (Hemachatus 
haemachatus), and Dendroaspis (D. angusticeps, D. jamesoni, and D. polylepis), and 
species of the genus Bitis (B. arietans and B. gabonica) of the Viperidae family. This 
antivenom is commonly available throughout the southern regions of Africa where 
Aspidelaps spp. are distributed [11]. For these reasons, we screened the 
immunological cross-reactivity of the SAIMR polyvalent antivenom with venoms from A. 
s. intermedius, A. l. lubricus and A. l. cowlesi, and used venom from the neurotoxic 
cobra N. nivea as a comparator. 
We first performed immunoblotting experiments to visualise the antivenom 
antibody (equine F(ab’)2) cross-reactivity with the proteins of the three Aspidelaps 
venoms, and that of N. nivea (Fig. 3A). The SAIMR polyvalent antivenom exhibited 
extensive recognition of the various Aspidelaps venom toxins, in a comparable inter-
specific manner. Extensive binding was observed to the abundant lower molecular 
weight proteins (3FTxs and PLA2), and to less abundant toxins of higher molecular 
weights. As anticipated, the intensity of antibody-protein bands was greatest in the N. 
nivea venom used for comparison.  
We next used ELISA experiments to quantitate the amount of binding (end-point 
titration ELISA) and the strength of binding (avidity ELISA). The end-point ELISA 
results demonstrated substantial decreases in binding from the positive control (N. 
nivea venom) to the three Aspidelaps spp. (Fig. 3B). Nonetheless, the antibody-venom 
protein binding levels were substantially higher than the baseline, demonstrating that 
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the SAIMR polyvalent antivenom recognises and binds extensively to Aspidelaps 
venom toxins. The end-point dilution titres observed for the three Aspidelaps venoms 
were identical (all were 1:62,500), and are therefore comparable to prior studies 
describing interactions between African snake venoms and polyvalent antivenoms [20], 
but, as anticipated, are lower than when using monospecific antivenoms and 
homologous venoms [32]. Although there were no quantitative differences in the end-
point dilutions observed between the three Aspidelaps species, the level of binding 
observed with A. s. intermedius venom at lower dilutions was noticeably higher than 
that of its two congeners (Fig. 3B). Contrastingly, the relative avidity ELISA revealed 
little difference in the strength of antibody binding observed between the venoms of N. 
nivea, A. l. lubricus and A. l. cowlesi (Fig. 3C). The concentration of the chaotropic 
agent (ammonium thiocyanate) required to reduce ELISA readings by 50% was the 
same for all three species (6M), although, in contrast with the end-point ELISA, it was 
noticeably lower for A. s. intermedius (4M) (Fig. 3C) – suggesting that the degree of 
venom variation observed between this species and its congeners (Fig. 2) may result in 
weaker antibody interactions with the SAIMR polyvalent antivenom. Despite this, 50% 
reductions in binding in the presence of 4M ammonium thiocyanate is highly 
comparable with prior studies using SAIMR polyvalent antivenom and various snake 
venoms that this product neutralises in vivo [20]. 
 
Antivenomics analysis of the preclinical efficacy of SAIMR antivenom toward 
Aspidelaps venom 
The toxin recognition landscape of SAIMR antivenom was also assessed using 
third-generation antivenomics [33]. Analysis of the concentration-dependent 
immunocapturing profile of SAIMR antivenom affinity columns toward the venom toxins 
of A. l. cowlesi (Fig. 4A, Table 3A) and A. l. lubricus (Fig. 4B, Table 3B) showed 
paraspecific immunoreactivity against all the Aspidelaps toxin classes. The maximal 
binding capacity of immobilised (7 mg) SAIMR F(ab')2 antibodies was 80.45 g and 
98.64 g of A. l. cowlesi and A. l. lubricus venom toxins respectively, which correspond 
to maximum capacities per vial (10 mL, 118.4 mg F(ab')2/mL) of 13.60 mg and 14.09 
mg of venom. It is worth noting that 41% (A. l. cowlesi) and 49% (A. l. lubricus) of the 
SAIMR antivenom's ability to bind Aspidelaps toxins corresponds to anti-3FTx 
antibodies. For a calculated average molecular mass of 10.6 kDa for the various 
venom proteins, these antivenomics results suggest that 5.9% and 7.3% of the SAIMR 
antibodies recognize toxins from A. l. cowlesi and A. l. lubricus, respectively. These 
figures fall within the low range of percentages of anti-toxin antibodies (4-24%) 
determined, however, in a yet still small number of commercial antivenoms (JJC, 
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unpublished results).     
 
In vivo neutralisation of Aspidelaps venom lethality by SAIMR polyvalent 
antivenom 
We next sought to assess whether the promising immunological cross-reactivity 
observed between the SAIMR polyvalent antivenom and Aspidelaps venoms (Figs. 3 
and 4, Table 3) would translate into the murine preclinical neutralisation of venom-
induced lethality in vivo. To this end, we performed median effective dose 50 (ED50) 
assays [35, 36] using A. s. intermedius venom and the SAIMR polyvalent antivenom, 
and compared these results with those obtained using venom from Naja nivea. For 
both experiments the mice were challenged with 2 LD50s of each venom. The SAIMR 
polyvalent antivenom effectively neutralised the lethal effects of both venoms, although 
it was more efficacious at lower doses against N. nivea venom. The ED50s against A. s. 
intermedius and N. nivea venoms were 24.52 µl antivenom per mouse [21.45-27.65 µl, 
95% CI] and 15.95 µl [13.96-18.23 µl, 95% CI]), respectively. The neutralising potency 
of the SAIMR antivenom (P, in milligrams of venom neutralized by 1 mL of antivenom), 
calculated as P = [(T -1)/DE50] x LD50, where Tis the number of LD50s [mg V/mouse] 
in the test dose of venom, and ED50 is the median effective dose of the antivenom in 
ml/mouse [64], was 0.235 mg venom/mL antivenom (A. s. intermedius) and 0.944 mg 
venom/mL antivenom (N. nivea).  
The percentage of antibodies that recognise Aspidelaps toxins and contribute to 
the lethality neutralising capacity of lethality of SAIMR antivenom can be calculated by 
the equation %neutralising F(ab')2 = (P/maximal venom binding capacity). Assuming 
that SAIMR potency against A. l. cowlesi and A. l. lubricus venoms lethality does not 
strongly depart from that determined for A. s. intermedius, 17.3% and 13.8% of A. l. 
cowlesi and A. l. lubricus toxin-recognising F(ab')2 molecules may also bear lethality 
neutralising activity. These findings strongly suggest that, although the SAIMR 
antivenom is four times less effective at neutralising A. s. intermedius venom than that 
of N. nivea, in the current absence of any Aspidelaps-specific antivenom, this 
polyvalent antivenom could be a useful therapeutic tool for treating human 
envenomings by Aspidelaps species. These findings will, however, require future 
clinical validation. 
 
CONCLUDING REMARKS 
Our results demonstrate that snakes of the genus Aspidelaps have venom abundant in 
3FTx and PLA2 toxins, but that A. s. intermedius and the A. lubricus subspecies 
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lubricus and cowlesi differ in terms of the abundance of 3FTx isoforms found in their 
venom. Despite these snakes having much smaller venom yields than many other 
African elapid snakes (e.g. mambas [Dendroapsis spp.] and cobras [Naja spp.]), due to 
their much smaller size, we demonstrate that members of this genus have highly toxic 
venom, whose effects are characterised by systemic neurotoxicity resulting in 
respiratory paralysis and notable cardiotoxic and haemotoxic pathologies in a murine 
model of envenoming. These findings correlate with the limited clinical information 
available relating to bites by Aspidelaps, and highlight that the toxicity of Aspidelaps 
venoms, on a weight by weight basis, is equivalent to that of cobras and mambas. 
However, the considerably higher venom volumes of the latter suggest that human 
systemic envenoming by Aspidelaps species may not be as life-threatening as that 
from cobras and mambas. We also demonstrate that the SAIMR polyspecific 
antivenom exhibits pre-clinical neutralising capability against the venom of A. s. 
intermedius, and probably also against the venoms of the A. lubricus subspecies. 
Thus, we recommend that this antivenom be trialled for its use in treating systemic 
envenoming by Aspidelaps snake species. 
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Table 1. Comparison of the A. s. intermedius venom gland transcriptome and venom 
proteome expressed as percentages of toxin gene expression (transcriptome) and of 
protein abundance (proteome) of key toxin families identified. Green bars, toxin type is 
present at a higher relative frequency in the venom proteome than in the transcriptome; 
red bars, toxin type is present at a lower relative frequency in the venom proteome 
than in the transcriptome. 
 
 
 
 
Table 2. Calculation of theoretical LD50s of Aspidelaps venoms via the application of a 
toxicovenomics approach, and the reported LD50s for major individual 3FTxs or 3FTx 
classes. ƒLD50, fraction of the theoretical LD50 contributed by the individual toxin 
listed in column "Toxin" and calculated as (%Toxin"i") x (LD50 of Toxin"i"). 
Percentages represent the relative abundance of the listed toxins (see pie charts 
displayed as panels B, D, and F of Fig.2). 
 
Toxin 
 
Refere
nces 
A. s. 
intermediu
s A. l. lubricus A. l. cowlesi 
  
 
            
 
 
LD50 
(g/g) 
 
5.75 2LD50  5 >5.0 
         
   
% 
⨍ 
LD50* % ⨍ LD50* % ⨍ LD50* 
   
            
LNTx 
S4C6 0.13 [17] 
28
.9 0.038 
40
.7 0.053 
41
.8 0.054 
         long a-
NTx 
  
2.
3 0.003 
  
1.
9 0.0025 
         
CTx S3C2 6.6 [18] 
10
.5 0.693 
2.
1 0.138 
4.
8 0.317 
         
CTx S4C8 9.4 [18] 
23
.2 2,181 
             PLA2  
CM-II 1.1 [15] 
6.
1 0.067 
5.
7 0.063 
4.
9 0.054 
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atratoxin 
b 0.18 [65] 
5.
2 0.009 
25
.6 0.046 
22
.1 0.040 
         short 
aNTxs 
0.04-0.3 [54] 
7.
3 0.004-
0.032 
1.
4 0.0017-
0.0126 
1.
6 0.002-
0.0153     other 
aNTxs 
3.
5 
2.
8 
3.
5 
wNTx 
CM-II 16.1 [66] 
1.
8 0.29 
             NTx 
P01434 0.08 [67] 
9.
6 0.008 
             -NTx  
P81782 0.06-0.13 [68] 
  
2.
1 0.026 
0.
97 0.0012 
         
nc3FTx 5-80 [69] 
  
3.
1 
0.16-
2.48 
2.
1 
0.11-
1.68 
         
𝝨 
   
3.29-
3.31 
 
0.49-
2.82 
 
0.59-
2.16 
Other 
toxins (22) 
 
11
.2 2.46 
16
.5 3.63 
16
.3 3.59 
         
 
Calculate
d LD50 
  
5.75-
5.77 
 
4.12-
6.45 
 
4.18-
5.75 
         
         * ⨍ LD50 = (%Toxin "i" ) x 
(LD50 Toxin "i") 
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Table 3. Total and concentration-dependent immunoretained (RET) A. l. cowlesi (A) 
and A. l. lubricus (B) venom proteins by SAIMR polyvalent antivenom affinity column. 
Maximal binding for each RP-HPLC fraction is highlighted by yellow background. 
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Fig. 1. The relative expression of transcripts encoding venom toxin classes 
identified in the A. s. intermedius venom gland transcriptome. The left pie chart 
shows toxin components with transcript abundances of >1% of all toxins, and the 
right pie chart shows a breakdown of components with <1% expression (‘others’). 
For those toxins that are more abundantly expressed, the number of contigs 
encoding each toxin family are displayed in parentheses (for details, consult 
Supplementary Table S1). Key: three-finger toxin (3FTx), phospholipase A2 (PLA2), 
Kunitz-type inhibitor domains (KUN), cysteine-rich secretory protein (CRISP), C-type 
natriuretic peptide (C-NP), snake venom metalloproteinase (SVMP), nawaprin 
(NAW), nerve growth factor (NGF), hyaluronidase (HYA), vespryn (VSPN), serine 
proteinase (SP), 5'-nucleotidase (5'NUC), phosphodiesterase (PDE), cobra venom 
factor (CVF), dipeptidyl peptidase-4 (DPPIV), L-amino acid oxidase (LAO) and 
phospholipase B (PLB). 
 
Fig. 2. Proteomic analyses of venom from three species of the genus Aspidelaps. 
Reverse-phase chromatographic separation of A. s. intermedius (Panel A), A. l. 
lubricus (Panel C) and A. l. cowlesi (Panel E) venom proteins. Insets, SDS–PAGE 
profiles of the various RP-HPLC isolated protein fractions analysed under non-
reduced (upper gels) and reduced (lower gels) conditions. Pie charts displayed in 
panels B, D and F, show, respectively, the relative occurrence (in percentage of 
total venom proteins) of toxins from different protein families in the venoms of A. s. 
intermedius, A. l. lubricus, and A. l. cowlesi. PIII-SVMP, snake venom 
metalloproteinse of class PIII; svNGF, snake venom nerve growth factor; n.i., not 
identified; other acronyms as in the legend of Fig. 1.  
 
Fig. 3. Immunological cross-reactivity between venom from Aspidelaps spp. and 
Naja nivea and the SAIMR polyvalent antivenom. A) Left panel: reduced SDS-
PAGE gel electrophoretic profile of the four venoms; right panel: immunoblot of the 
SDS-PAGE with SAIMR polyvalent antivenom. B) End point titration curves showing 
the immunological binding between each venom and the SAIMR polyvalent 
antivenom with a five-fold dilution factor across the x-axis. C) Avidity titration curves 
showing the immunological binding between each venom and the SAIMR polyvalent 
antivenom in the presence of a chaotrope (ammonium thiocyanate), which is diluted 
across the x-axis. Key: ALL: A. l. lubricus; ALC: A. l. cowlesi; ASI: A. s. intermedius; 
NIV: N. nivea. 
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Fig. 4. Third-generation antivenomic analyses of A. l. cowlesi and A. l. lubricus 
venom with SAIMR polyvalent antivenom. Reverse-phase chromatographic analysis 
of whole venom (panel a) and of the non-retained and the immunoretained fractions 
recovered from affinity column (7 mg immobilised SAIMR antivenom F(ab')2 molecules) 
incubated with increasing amounts (100-1200 g) of venom from A. l. cowlesi (A) and 
A. l. lubricus (B) (panels b-i). Panels j-l, retained and non-retained venom fractions on 
mock matrix and naïve equine IgG affinity columns. 
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Highlights 
 
 The venom proteomes of Aspidelaps scutatus and A. lubricus subspecies were 
characterised. 
 Consistent with the predominance of 3FTxs, murine envenoming by A. s. intermedius 
induced systemic neurotoxicity.  
 Antivenomics analysis revealed extensively recognision of Aspidelaps venom toxins by 
the SAIMR polyvalent antivenom. 
 The SAIMR antivenom neutralised the mouse lethal activity of A. s. intermedius venom 
with a potency of 0.235 mg venom/mL antivenom.  
 Our data suggest that SAIMR antivenom could be a useful therapeutic tool against 
human envenomings by Aspidelaps species. 
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